Dr. Nicholas Lydon CML Chronic myeloid leukemia
''Nicholas B. Lydon is a British scientist and entrepreneur. He won 2009 Lasker Clinical Award for the development of Gleevec, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukemia (CML). Lydon earned a BS in biochemistry from the University of Leeds, England and received his Ph.D in biochemistry from the University of Dundee, Scotland.''
Extract of http://en.wikipedia.org/wiki/Nicholas_Lydon
Extract of http://en.wikipedia.org/wiki/Nicholas_Lydon
VIDEOS
2009 Lasker DeBakey Clinical Medical Research Award
March 9, 2016, Albert and Mary Lasker Foundation
Targeting the human kinome: cancer drug discovery
September 26, 2014, The Royal Society
2012 (28th) Japan Prize: Dr. Rowley / Dr. Druker / Dr. Lydon
April 24, 2012, JapanPrize
2009 Lasker DeBakey Clinical Medical Research Award
March 9, 2016, Albert and Mary Lasker Foundation
ARTICLES
" Gleevec: From Bench to Clinic"
November 2004, UC Santa Barbara
